Background: About 10% of patients with arterial hypertension have a positive screening test for primary aldosteronism (PA) and 50% to 70% of them have a negative confirmatory test: the appropriate follow-up of these patients is currently unknown. We investigate the incidence of PA in patients with previous negative confirmatory testing, after at least a 2-year follow-up. Methods: One hundred eighty-four patients with a previously elevated aldosterone-to-renin ratio followed by a negative confirmatory test were recruited in 2 hypertension centers (Torino and Munich). We repeated the screening test for PA and, if positive, the confirmatory test (seated saline infusion test or captopril challenge test). Primary end point of the study was the incidence of newly diagnosed overt PA, as defined by a positive confirmatory test. Results: After a mean follow-up of 5 years, 20% of patients developed overt PA. When subtype diagnosis was offered systematically, one-third of patients displayed unilateral PA. Patients who developed PA showed worsening of blood pressure control and a higher rate of cardiac organ damage, despite similar implementation of antihypertensive therapy, compared with patients without PA. A mild progression of autonomous aldosterone secretion was evident even in patients without confirmed PA but with relatively stable control of blood pressure levels over time. Conclusions: About one-fifth of patients with a negative confirmatory test develop overt PA over time. A clinical follow-up of patients with a negative confirmatory test is advisable, along with the repetition of PA investigation, primarily in patients with worsening of blood pressure control.
Long-Term Follow-Up of Patients With Elevated Aldosterone-to-Renin Ratio but Negative Confirmatory Test: The Progression of Primary Aldosteronism Phenotypes
Buffolo, FabrizioCo-first
;Pecori, AlessioCo-first
;Veglio, Franco;Mengozzi, Giulio;Mulatero, Paolo
;Monticone, SilviaCo-last
2024-01-01
Abstract
Background: About 10% of patients with arterial hypertension have a positive screening test for primary aldosteronism (PA) and 50% to 70% of them have a negative confirmatory test: the appropriate follow-up of these patients is currently unknown. We investigate the incidence of PA in patients with previous negative confirmatory testing, after at least a 2-year follow-up. Methods: One hundred eighty-four patients with a previously elevated aldosterone-to-renin ratio followed by a negative confirmatory test were recruited in 2 hypertension centers (Torino and Munich). We repeated the screening test for PA and, if positive, the confirmatory test (seated saline infusion test or captopril challenge test). Primary end point of the study was the incidence of newly diagnosed overt PA, as defined by a positive confirmatory test. Results: After a mean follow-up of 5 years, 20% of patients developed overt PA. When subtype diagnosis was offered systematically, one-third of patients displayed unilateral PA. Patients who developed PA showed worsening of blood pressure control and a higher rate of cardiac organ damage, despite similar implementation of antihypertensive therapy, compared with patients without PA. A mild progression of autonomous aldosterone secretion was evident even in patients without confirmed PA but with relatively stable control of blood pressure levels over time. Conclusions: About one-fifth of patients with a negative confirmatory test develop overt PA over time. A clinical follow-up of patients with a negative confirmatory test is advisable, along with the repetition of PA investigation, primarily in patients with worsening of blood pressure control.File | Dimensione | Formato | |
---|---|---|---|
ROARR Figure 1 1st submission.tif
Accesso aperto
Tipo di file:
PREPRINT (PRIMA BOZZA)
Dimensione
716 kB
Formato
TIFF
|
716 kB | TIFF | Visualizza/Apri |
ROARR Figure 2 1st submission.tif
Accesso aperto
Tipo di file:
PREPRINT (PRIMA BOZZA)
Dimensione
1.23 MB
Formato
TIFF
|
1.23 MB | TIFF | Visualizza/Apri |
ROARR_manuscript 1st submission_FB.docx
Accesso aperto
Tipo di file:
PREPRINT (PRIMA BOZZA)
Dimensione
695.69 kB
Formato
Microsoft Word XML
|
695.69 kB | Microsoft Word XML | Visualizza/Apri |
JCEM Buffolo.pdf
Accesso aperto
Dimensione
621.14 kB
Formato
Adobe PDF
|
621.14 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.